Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I, Open-label Study of the ATM Inhibitor M4076 in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 410)

NCT04882917 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT04882917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04882917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I, Open-label Study of the ATM Inhibitor M4076 in Participants With Advanced Solid Tumors (DDRiver Solid Tumors 410)
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 24, 2021
Completion date
March 31, 2023
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors